Therefore, the use of DPP4 inhibitors (gliptins) in COVID-19 management should be better exploited to improve the overall knowledge on how DPP4 may be useful to design novel therapies to block SARS-CoV-2 entry (33). This evidence concerns the gene DPP4 and COVID-19.